Developer docs
API playgroundTry for free, no card

Search company profiles

Longevica

Full company profile

uuid0003re6

Namestring
Longevica
Legal namestring
Longevica Therapeutics
Websiteurl
longevica.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Longevica Therapeutics is a US preclinical-stage biotech (founded 2009, headquartered in Belmont, California) whose stated mission is to identify mechanisms of human life extension. The company has built what it describes as the world's largest mouse longevity screening program, testing 1,033 compounds across more than 20,000 mice, and reports that 60+ compounds extended lifespan by over 10% and 5 compounds by 16–22%. Its core technology stack centers on a Longevity AI Platform trained on this proprietary dataset, combined with bioinformatics and systems biology methods, aimed at accelerating human longevity drug discovery and identifying candidate compounds for translational development. In November 2021 the company also launched an Open Research Platform providing external scientists with access to its data and screening infrastructure.

The company is pursuing a multi-track commercialization strategy: (1) human healthspan therapeutics and supplements advancing toward IND-enabling trials, (2) pet longevity supplements and therapies, (3) IP licensing and patent monetization around key longevity compounds (including a granted US patent for a life-extending method), and (4) platform access for academic and pharmaceutical partners. GTM motion is primarily enterprise/B2B — direct investor outreach, pitch-deck distribution, and partnership development with pharmaceutical and research-institution counterparts. Longevica has disclosed $15.5M in cumulative funding, most recently a $2.5M round led by Xploration Capital in November 2021, and operates with a small (1–10) employee base supplemented by an advisory bench drawn from Harvard, UC Berkeley, and Rutgers.

Revenue is not publicly disclosed; no commercial therapeutic product is yet on market, and the company characterizes itself as actively fundraising to support advanced R&D and commercial translation. The hybrid B2B/B2C customer strategy — health-conscious consumers, pet owners, pharma licensors, and academic researchers — has not yet translated into named customer relationships or material revenue per the available data.

Short descriptiontext

Longevica Therapeutics is a US preclinical biotech that has run the world's largest mouse longevity screen (1,033 compounds, 20,000+ mice) and is building an AI-trained drug discovery platform to develop human and pet healthspan therapeutics, supplements, and licensed IP.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
longevity therapeutics, AI drug discovery, mouse longevity studies, healthspan supplements, translational research
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYTHAJAHAI
Medical Wellness & Longevity (Health Screening, Biohacking, Anti-aging Programs)
Travel & Hospitality/Tours, Attractions & Experiences/Wellness & Spa Experiences (Retreats, Thermal Baths, Yoga)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Longevity Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Science-backed Therapies and Supplements
TypeOne Time License
Description

Developing and commercializing science-backed therapies and supplements for human healthspan extension and pet longevity. Moving into translational research, IND-enabling studies, and supplement safety monitoring.

longevica.com
2Longevity Research Platform Access
TypeSubscription Recurring
Description

Open research platform for studying pharmacological compounds, providing access to data and infrastructure for scientific research, supporting development of consumer-ready products.

longevica.com
3IP Licensing and Patent Monetization
TypeLicensing Royalties
Description

Strong patent portfolio on key longevity compounds with potential for licensing and patent monetization. Recently obtained US patent for life-extending method.

longevica.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Longevica conducts the world's largest mouse longevity studies and uses the resulting proprietary dataset to train an AI-driven drug discovery platform aimed at accelerating human longevity therapeutics. Building on this research base, the company develops science-backed therapies and supplements for human and pet healthspan, while providing an open research platform for external researchers and IND-enabling translational research services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60+ compounds extended lifespan by over 10% in mouse studies
+3 more records
Product overview1 text field

Longevica is a life science company that has conducted the world's largest mouse longevity studies (testing over 1,033 compounds on 20,000 mice). The company offers an integrated portfolio consisting of an Open Research Platform providing external access to their longevity data and infrastructure, a Longevity AI Platform for AI-driven drug discovery, Human Healthspan & Longevity Therapeutics (science-backed therapies and supplements), Pet Health & Longevity products, and Translational Research & Clinical Development services. The company is moving from foundational research into translational research and clinical development to bring real-world impact to patients, consumers, and their pets.

Product and service5 records
1Open Research Platform
CategoryResearch platform / data access
Description

Open research platform providing external access to Longevica's longevity research data and screening infrastructure for studying pharmacological compounds related to aging and life extension.

2Longevity AI Platform
CategoryAI drug discovery platform
Description

AI-driven drug discovery platform trained on the world's largest longevity screening dataset from mouse studies, designed to accelerate the identification and development of human longevity drugs by combining bioinformatics, systems biology, and AI approaches.

3Human Healthspan & Longevity Therapeutics
CategoryLongevity therapeutics and supplements
Description

Science-backed therapies and supplements developed to help people live longer, healthier lives by extending human healthspan.

4Pet Health & Longevity
CategoryPet longevity products
Description

Cutting-edge supplements and therapies developed to help pets live longer, healthier, and happier lives.

5Translational Research & Clinical Development
CategoryTranslational research services
Description

IND-enabling studies and supplement safety monitoring services that advance promising longevity compounds from research through clinical development, including nutrivigilance for supplements.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Adrian Salic, Professor at Harvard, serves as Scientific Advisor, contributing expertise in cell signaling and Hedgehog pathway research that led to development of Click-iT kits.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Steven Garan, Director of CRE Aging at UC Berkeley, serves as Chief Scientific and Technology Advisor. Known for inventing AIMS, coining 'Phenomics', and work on caloric restriction effects.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Alexey Ryazanov, Professor at Rutgers, serves as Scientific Advisor with over 20 years of experience in molecular biology and aging mechanisms research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company using proprietary datasets and generative models to identify novel therapeutics, including in aging/longevity. Directly comparable to Longevica's AI longevity platform thesis and pipeline approach.

TypeDirect peer
Description

AI-enabled drug discovery company generating proprietary biological datasets at scale to power ML-driven target identification and translational pipelines. Comparable technology stack, data-centric moat, and small-molecule development model.

TypeBroad incumbent
Description

Well-capitalized (~$3B) longevity biotech pursuing cellular rejuvenation programming. Operates in the same longevity therapeutic space with vastly greater resources and a broader biological reprogramming approach.

TypeBroad incumbent
Description

Alphabet-funded longevity R&D company with deep resources focused on aging biology and therapeutics. Same longevity drug-discovery thesis, but with vastly larger capital base and longer investment horizon.

TypeDirect peer
Description

Clinical-stage biotech using AI and human cohort data to identify therapeutics that target aging biology. Comparable discovery thesis combining proprietary datasets with translational drug development in longevity indications.

TypeDirect peer
Description

Clinical-stage longevity biotech developing senolytic therapeutics to address age-related diseases. Direct competitor in the aging-pharmaceutical space, with more advanced clinical assets but similar translational risk.

TypeDirect peer
Description

Longevity consumer supplements company built on aging-biology research (NAD+, cellular health). Comparable supplement commercialization angle and longevity science positioning, though Elysium is consumer-only without drug discovery.

TypeDirect peer
Description

Pet longevity biotech developing FDA-conditional drugs to extend dog lifespan. Direct peer on Longevica's pet longevity product line, with similar regulatory pathway challenges in animal healthspan.

TypeDirect peer
Description

Longevity biotech pursuing multiple partial reprogramming and gene therapy programs to address aging. Operates in the same aging-therapeutics space with comparable platform ambitions and translational stage.

TypeEmerging player
Description

Consumer longevity brand offering epigenetic age testing and supplements. Adjacent consumer-facing longevity play that overlaps with Longevica's supplement ambitions but lacks drug-discovery operations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Longevica

Longevity Therapeuticslongevica.com

Longevica Therapeutics is a US preclinical biotech that has run the world's largest mouse longevity screen (1,033 compounds, 20,000+ mice) and is building an AI-trained drug discovery platform to develop human and pet healthspan therapeutics, supplements, and licensed IP.

What Longevica does

Longevica Therapeutics is a US preclinical-stage biotech (founded 2009, headquartered in Belmont, California) whose stated mission is to identify mechanisms of human life extension. The company has built what it describes as the world's largest mouse longevity screening program, testing 1,033 compounds across more than 20,000 mice, and reports that 60+ compounds extended lifespan by over 10% and 5 compounds by 16–22%. Its core technology stack centers on a Longevity AI Platform trained on this proprietary dataset, combined with bioinformatics and systems biology methods, aimed at accelerating human longevity drug discovery and identifying candidate compounds for translational development. In November 2021 the company also launched an Open Research Platform providing external scientists with access to its data and screening infrastructure.

The company is pursuing a multi-track commercialization strategy: (1) human healthspan therapeutics and supplements advancing toward IND-enabling trials, (2) pet longevity supplements and therapies, (3) IP licensing and patent monetization around key longevity compounds (including a granted US patent for a life-extending method), and (4) platform access for academic and pharmaceutical partners. GTM motion is primarily enterprise/B2B — direct investor outreach, pitch-deck distribution, and partnership development with pharmaceutical and research-institution counterparts. Longevica has disclosed $15.5M in cumulative funding, most recently a $2.5M round led by Xploration Capital in November 2021, and operates with a small (1–10) employee base supplemented by an advisory bench drawn from Harvard, UC Berkeley, and Rutgers.

Revenue is not publicly disclosed; no commercial therapeutic product is yet on market, and the company characterizes itself as actively fundraising to support advanced R&D and commercial translation. The hybrid B2B/B2C customer strategy — health-conscious consumers, pet owners, pharma licensors, and academic researchers — has not yet translated into named customer relationships or material revenue per the available data.

Longevica firmographics

Firmographics
Name
Longevica
Legal name
Longevica Therapeutics
Website
https://longevica.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Longevica Therapeutics is a US preclinical biotech that has run the world's largest mouse longevity screen (1,033 compounds, 20,000+ mice) and is building an AI-trained drug discovery platform to develop human and pet healthspan therapeutics, supplements, and licensed IP.
Ownership category
akta.pro rank

Longevica industry classification

Industry
Product category
Longevity Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYTHAJAHAI
Medical Wellness & Longevity (Health Screening, Biohacking, Anti-aging Programs)
Travel & Hospitality/Tours, Attractions & Experiences/Wellness & Spa Experiences (Retreats, Thermal Baths, Yoga)

Keywords

  • Longevity therapeutics
  • AI drug discovery
  • Mouse longevity studies
  • Healthspan supplements
  • Translational research

Where Longevica is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Longevica business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Science-backed Therapies and Supplements: Developing and commercializing science-backed therapies and supplements for human healthspan extension and pet longevity. Moving into translational research, IND-enabling studies, and supplement safety monitoring.
  2. Longevity Research Platform Access: Open research platform for studying pharmacological compounds, providing access to data and infrastructure for scientific research, supporting development of consumer-ready products.
  3. IP Licensing and Patent Monetization: Strong patent portfolio on key longevity compounds with potential for licensing and patent monetization. Recently obtained US patent for life-extending method.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Longevica product offering

Product offering

Core offering

Longevica conducts the world's largest mouse longevity studies and uses the resulting proprietary dataset to train an AI-driven drug discovery platform aimed at accelerating human longevity therapeutics. Building on this research base, the company develops science-backed therapies and supplements for human and pet healthspan, while providing an open research platform for external researchers and IND-enabling translational research services.

Product overview

Longevica is a life science company that has conducted the world's largest mouse longevity studies (testing over 1,033 compounds on 20,000 mice). The company offers an integrated portfolio consisting of an Open Research Platform providing external access to their longevity data and infrastructure, a Longevity AI Platform for AI-driven drug discovery, Human Healthspan & Longevity Therapeutics (science-backed therapies and supplements), Pet Health & Longevity products, and Translational Research & Clinical Development services. The company is moving from foundational research into translational research and clinical development to bring real-world impact to patients, consumers, and their pets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Open Research Platform Open research platform providing external access to Longevica's longevity research data and screening infrastructure for studying pharmacological compounds related to aging and life extension.
  • Longevity AI Platform AI-driven drug discovery platform trained on the world's largest longevity screening dataset from mouse studies, designed to accelerate the identification and development of human longevity drugs by combining bioinformatics, systems biology, and AI approaches.
  • Human Healthspan & Longevity Therapeutics Science-backed therapies and supplements developed to help people live longer, healthier lives by extending human healthspan.
  • Pet Health & Longevity Cutting-edge supplements and therapies developed to help pets live longer, healthier, and happier lives.
  • Translational Research & Clinical Development IND-enabling studies and supplement safety monitoring services that advance promising longevity compounds from research through clinical development, including nutrivigilance for supplements.

Quantifiable outcome

  • 60+ compounds extended lifespan by over 10% in mouse studies
  • +3 more outcomes

Companies that use Longevica

Customer profile

Segments4 records

Ideal customer profiles5 records

Longevica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Longevica partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • Harvard UniversityminorStrategic or Co-development PartnerDr. Adrian Salic, Professor at Harvard, serves as Scientific Advisor, contributing expertise in cell signaling and Hedgehog pathway research that led to development of Click-iT kits.
  • UC BerkeleyminorStrategic or Co-development PartnerDr. Steven Garan, Director of CRE Aging at UC Berkeley, serves as Chief Scientific and Technology Advisor. Known for inventing AIMS, coining 'Phenomics', and work on caloric restriction effects.
  • Rutgers UniversityminorStrategic or Co-development PartnerDr. Alexey Ryazanov, Professor at Rutgers, serves as Scientific Advisor with over 20 years of experience in molecular biology and aging mechanisms research.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Longevica competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery company using proprietary datasets and generative models to identify novel therapeutics, including in aging/longevity. Directly comparable to Longevica's AI longevity platform thesis and pipeline approach.
  • Recursion Pharmaceuticals: AI-enabled drug discovery company generating proprietary biological datasets at scale to power ML-driven target identification and translational pipelines. Comparable technology stack, data-centric moat, and small-molecule development model.
  • BioAge Labs: Clinical-stage biotech using AI and human cohort data to identify therapeutics that target aging biology. Comparable discovery thesis combining proprietary datasets with translational drug development in longevity indications.
  • Unity Biotechnology: Clinical-stage longevity biotech developing senolytic therapeutics to address age-related diseases. Direct competitor in the aging-pharmaceutical space, with more advanced clinical assets but similar translational risk.
  • Elysium Health: Longevity consumer supplements company built on aging-biology research (NAD+, cellular health). Comparable supplement commercialization angle and longevity science positioning, though Elysium is consumer-only without drug discovery.
  • Loyal for Dogs: Pet longevity biotech developing FDA-conditional drugs to extend dog lifespan. Direct peer on Longevica's pet longevity product line, with similar regulatory pathway challenges in animal healthspan.
  • Life Biosciences: Longevity biotech pursuing multiple partial reprogramming and gene therapy programs to address aging. Operates in the same aging-therapeutics space with comparable platform ambitions and translational stage.

Broad incumbents

  • Altos Labs: Well-capitalized (~$3B) longevity biotech pursuing cellular rejuvenation programming. Operates in the same longevity therapeutic space with vastly greater resources and a broader biological reprogramming approach.
  • Calico Life Sciences: Alphabet-funded longevity R&D company with deep resources focused on aging biology and therapeutics. Same longevity drug-discovery thesis, but with vastly larger capital base and longer investment horizon.

Emerging players

  • Tally Health: Consumer longevity brand offering epigenetic age testing and supplements. Adjacent consumer-facing longevity play that overlaps with Longevica's supplement ambitions but lacks drug-discovery operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Longevica social profiles

Digital presence

Longevica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Longevica leadership team

Management profile

Number of profiles

Profiles14 records

Longevica funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Longevica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longevica

What does Longevica do?

Longevica conducts the world's largest mouse longevity studies and uses the resulting proprietary dataset to train an AI-driven drug discovery platform aimed at accelerating human longevity therapeutics. Building on this research base, the company develops science-backed therapies and supplements for human and pet healthspan, while providing an open research platform for external researchers and IND-enabling translational research services.

Is Longevica a public or private company?

Longevica is a private company. It is classified as venture growth investor backed and is currently operating.

When was Longevica founded?

Longevica was founded in 2009. It employs 1 to 10 people.

Where is Longevica based?

Longevica is headquartered in Princeton, United States, in the North America region.

How does Longevica make money?

Three revenue lines are on record. Science-backed Therapies and Supplements are the primary driver. The others are longevity Research Platform Access and IP Licensing and Patent Monetization.

Who are Longevica's main competitors?

Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, BioAge Labs, Unity Biotechnology, Elysium Health, Loyal for Dogs and Life Biosciences. Broad incumbents are Altos Labs and Calico Life Sciences. Tally Health is listed as an emerging player.

Does Longevica have an API?

No public API is recorded for Longevica.

What industry is Longevica in?

Longevica's product category is Longevity Therapeutics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyLongevica turns 16k mice into a health-and-lifespan drug pipelineLongevica reports a four-year mouse lifespan screen at The Jackson Laboratory that identified over 60 life-extending compounds, with some extending lifespan by up to 22%. The company plans to develop drugs based on new mechanisms and test compounds against age-related diseases, with a new CEO and advisory board.Longevity.TechnologyLongevica forms advisory board to advance longevity therapeuticsLongevica Therapeutics formed a scientific advisory board and appointed Dr. Prasun Mishra as CEO, shifting to clinical execution. The company invested $13 million over four years in an in vivo study at The Jackson Laboratory, identifying 60 compounds that extended mammalian lifespan by 10-22 percent. It plans to develop two novel therapeutic classes and repurpose existing molecules.FinancialContent Business PageBeyond Cellular Models: Longevica Capitalizes on World’s Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan PipelineLongevica Therapeutics announced its Scientific Advisory Board, led by CEO Dr. Prasun Mishra, to translate its $13 million, four-year in vivo mammalian longevity study into therapeutics. The study screened 1,033 compounds across 16,000 subjects, yielding two novel drug classes and repurposing programs. The company aims to advance these into preclinical development and clinical translation.Business Wire BlogBeyond Cellular Models: Longevica Capitalizes on World’s Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan PipelineLongevica Therapeutics announced its Scientific Advisory Board, led by CEO Dr. Prasun Mishra, to translate its $13M, 16,000-subject mammalian longevity study into therapeutics. The company will develop novel lifespan-extending drugs and repurpose compounds for age-related diseases, with pet health applications.Longevity.TechnologyLongevica hires drug-approval veteran as CEOLongevica Therapeutics appointed Prasun Mishra, an ex-Genentech executive, as CEO to lead its preclinical longevity program. The company spent $13 million over four years screening 1,033 compounds in over 16,000 mice, identifying new lifespan-extension mechanisms. Mishra will advance these leads into clinical trials and seek partnerships.FierceBiotechChutes & Ladders—Neumora shuffles leadership ahead of INDNeumora Therapeutics appointed Joshua Pinto as CEO ahead of its IND submission for an obesity treatment, while Juvena Therapeutics named Julie Anne Smith as CEO to guide phase 2 neuromuscular studies. These leadership changes are part of a broader industry roundup that also includes executive appointments at Longevica, 4C Biomed, and several other biotech firms.citybizLongevica Therapeutics Names Prasun Mishra CEO to Advance Longevity Drug PipelineLongevica Therapeutics has appointed Dr. Prasun Mishra as CEO to lead its transition from discovery research to preclinical drug development for longevity therapies. This strategic shift leverages data from a $13 million, four-year screening program conducted at The Jackson Laboratory involving over 16,000 mice. The company plans to use these findings to identify biological mechanisms and advance small-molecule candidates into IND-enabling studies.Business Wire BlogLongevica Therapeutics Appoints Ex-Genentech Biotech Veteran Dr. Prasun Mishra as CEO to Advance World's Largest $13 Million Mammalian Longevity Study Toward Clinical DevelopmentLongevica Therapeutics appointed Dr. Prasun Mishra, former Genentech/Roche and NIH leader, as CEO. The company's $13 million, four-year mammalian longevity study screened 1,033 compounds across 16,000 mice, identifying two new lifespan-extension mechanisms. Mishra will lead IND-enabling studies and strategic partnerships.Geeky GadgetsLongevica smart medication dispenser hits Kickstarter from $199Longevica has launched a Kickstarter campaign for its Smart Health Base, a smart medication dispenser and health monitoring device priced from $199. The device is designed to manage medication schedules, track vital health information, and provide real-time updates on users' Healthy Aging Index. If the funding goal is met, worldwide shipping is expected to begin around January 2023.PR NewswireLongevica to Launch an Open Research Platform to Accelerate the Discovery of Life Extension MechanismsLongevica, a life science company based in Princeton, New Jersey, announced plans to launch an open-source research platform for longevity science and secured $2.5 million in funding led by Xploration Capital. The platform will enable scientists worldwide to conduct pharmacological screening experiments using Longevica's proprietary dataset, which was built over 11 years with a $13 million investment and contains the largest study of 1,033 compounds. In initial experiments, the research team identified compounds demonstrating a 16 to 22 percent life extension effect, and a new study will test 300 additional compounds at Jackson Laboratory.